Finance

Beta
Lists
ONCY:NASDAQ
Oncolytics Biotech Inc
$0.95
+2.99%
(+0.027) 1D
$0.96
+1.29% (+0.012)
After hours
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ONCY...
Open
$0.92
High
$0.96
Low
$0.91
Mkt. cap
113.16M
Avg. vol.
1.45M
Volume
777.05K
52-wk high
$1.51
52-wk low
$0.71
Beta
1.07
Shares outstanding
119.35M
No. of employees
29
Open
$0.92
High
$0.96
Low
$0.91
Mkt. cap
113.16M
Avg. vol.
1.45M
Volume
777.05K
52-wk high
$1.51
52-wk low
$0.71
Beta
1.07
Shares outstanding
119.35M
No. of employees
29
News stories
From sources across the web
Profile
Oncolytics Biotech Inc. is a biotech company headquartered in San Diego, California, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
About Oncolytics Biotech Inc
CEO-
Employees29
Founded1998
HeadquartersCalgary, Alberta, Canada
SectorBiotechnology
Websiteoncolyticsbiotech.com
Analyst ratings
Based on 4 analysts giving stock ratings to ONCY in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for ONCY in the last 3 months.
Highest
Current $0.95
$10.00 (+955.07%)
Average
$6.00 (+533.04%)
Lowest
$3.00 (+216.52%)
Analyst
Recommendation
Action
Price target
Projected
Date
Boris Peaker
JonesTrading
Hold
Maintained
-
-
06/18/2026
Chad Messer
Lake Street
Buy
Maintained
$5.00
+427.5%
06/01/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$10.00
+955.1%
05/29/2026
Jason McCarthy
Maxim Group
Buy
Reiterated
$3.00
+216.5%
05/21/2026
Soumit Roy
JonesTrading
Hold
Maintained
-
-
04/06/2026
Previous reportsAll values in CAD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CAD
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
2.81M
7.52M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
2.90M
6.32M
Operating expense
-
-
5.71M
13.84M
Total operating expenses
-
-
5.71M
13.84M
Operating income
-
-
-5.71M
-13.84M
Other non operating income
-
-
-196.00K
-1.05M
EBT including unusual items
-
-
-6.08M
-14.65M
EBT excluding unusual items
-
-
-6.08M
-14.65M
Income tax expense
-
-
85.00K
-252.00K
Effective tax rate
-
-
-1.40%
1.72%
Other operating expenses
-
-
-
-
Net income
-
-
-6.16M
-14.40M
Net profit margin
-
-
-
-
Earnings per share
-0.10
-0.08
-0.07
-0.14
Interest and investment income
-
-
104.00K
100.00K
Interest expense
-
-
-
-
Net interest expenses
-
-
104.00K
100.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-5.68M
-13.82M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of ONCY
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer